A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

BACKGROUND AND PURPOSE: Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) wit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Springerplus
Autors principals: Foster, Graham R., Chayama, Kazuaki, Chuang, Wan-Long, Fainboim, Hugo, Farkkila, Martti, Gadano, Adrian, Gaeta, Giovanni B., Hézode, Christophe, Inada, Yukiko, Heo, Jeong, Kumada, Hiromitsu, Lu, Sheng-Nan, Marcellin, Patrick, Moreno, Christophe, Roberts, Stuart K., Strasser, Simone I., Thompson, Alexander J., Toyota, Joji, Paik, Seung Woon, Vierling, John M., Zignego, Anna L., Cohen, David, McPhee, Fiona, Wind-Rotolo, Megan, Srinivasan, Subasree, Hruska, Matthew, Myler, Heather, Portsmouth, Simon D.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4990525/
https://ncbi.nlm.nih.gov/pubmed/27588258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-016-2920-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars